Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 1:16:1599674.
doi: 10.3389/fimmu.2025.1599674. eCollection 2025.

Noncoding RNAs as regulators of FOSL1 in cancer

Affiliations
Review

Noncoding RNAs as regulators of FOSL1 in cancer

Xiaochang Wang et al. Front Immunol. .

Abstract

The AP-1 transcription factor FOSL1, also known as Fra-1, is a crucial oncoprotein that plays an important role in human tumor progression and metastasis and has thus emerged as a promising therapeutic target. FOSL1 regulates the expression of a large protein-coding gene network, and this molecular mechanism can promote the progression of tumors. Interestingly, recent studies have shown that FOSL1 can also achieve the same protumor effect by regulating certain noncoding RNAs (ncRNAs). However, more studies have shown that ncRNAs can regulate the expression and activity of FOSL1, thereby affecting the occurrence and development of tumors, which indicates that ncRNAs can be regulators of FOSL1 in cancer. In this review, we first provide a comprehensive overview of the expression and function of FOSL1 and ncRNAs in tumors and then focus on the mutual regulatory relationship between ncRNAs and FOSL1, as well as their regulatory effects on and mechanisms of tumor progression. In addition, we further explored the potential clinical applications of the FOSL1-ncRNA system in cancer treatment, providing a theoretical basis for the study of FOSL1 and/or ncRNA-related molecular markers or targeted therapies.

Keywords: FOSL1; cancer; immune escape; ncRNA; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The protumor effects of FOSL1 Fra-1/FOSL1 can promote tumor growth, proliferation, and metastasis, EMT, immune escape, and drug resistance and inhibit apoptosis by activating or inhibiting cancer-related genes or affecting tumor-associated signal transduction pathways.
Figure 2
Figure 2
The regulatory function of ncRNAs in cancer ncRNAs are a double-edged sword in the occurrence and development of cancer. On the one hand, ncRNAs can promote tumor cell invasion, proliferation, immune escape, metastasis, or drug resistance by influencing enzymes, cyclins, or metabolic reprogramming but promote apoptosis via ceRNAs, transcription, and epigenetic regulation. On the other hand, ncRNAs can regulate tumor-associated macrophages or cancer-associated fibroblasts by affecting tumor suppressor genes, transcription, translation, or immunoreactions. They can also inhibit tumor metastasis, proliferation, invasion, EMT, or angiogenesis by regulating the tumor microenvironment and regulatory factors of the cell cycle.
Figure 3
Figure 3
The ncRNA-mediated mechanisms by which FOSL1 affects various tumors Different types of ncRNAs mediate the activation or inhibition of Fra-1/FOSL1 through many signaling pathways, thereby affecting the progression of various tumors.

Similar articles

References

    1. Schiefer AI, Vesely P, Hassler MR, Egger G, Kenner L. The role of AP-1 and epigenetics in ALCL. Front Biosci (Schol Ed). (2015) 7:226–35. doi: 10.2741/s436, PMID: - DOI - PubMed
    1. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. (1987) 49:729–39. doi: 10.1016/0092-8674(87)90611-8, PMID: - DOI - PubMed
    1. Bhosale PB, Kim HH, Abusaliya A, Vetrivel P, Ha SE, Park MY, et al. Structural and functional properties of activator protein-1 in cancer and inflammation. Evid Based Complement Alternat Med. (2022) 2022:9797929. doi: 10.1155/2022/9797929, PMID: - DOI - PMC - PubMed
    1. Liebermann DA, Gregory B, Hoffman B. AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. Int J Oncol. (1998) 12:685–700. doi: 10.3892/ijo.12.3.685, PMID: - DOI - PubMed
    1. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. (1997) 9:240–6. doi: 10.1016/S0955-0674(97)80068-3, PMID: - DOI - PubMed

LinkOut - more resources